550 related articles for article (PubMed ID: 29789716)
1. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression.
Ji X; Qian J; Rahman SMJ; Siska PJ; Zou Y; Harris BK; Hoeksema MD; Trenary IA; Heidi C; Eisenberg R; Rathmell JC; Young JD; Massion PP
Oncogene; 2018 Sep; 37(36):5007-5019. PubMed ID: 29789716
[TBL] [Abstract][Full Text] [Related]
2. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.
Koppula P; Zhuang L; Gan B
Protein Cell; 2021 Aug; 12(8):599-620. PubMed ID: 33000412
[TBL] [Abstract][Full Text] [Related]
3. The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate.
Koppula P; Zhang Y; Shi J; Li W; Gan B
J Biol Chem; 2017 Aug; 292(34):14240-14249. PubMed ID: 28630042
[TBL] [Abstract][Full Text] [Related]
4. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
[TBL] [Abstract][Full Text] [Related]
5. Kinetic analysis of cystine uptake and inhibition pattern of sulfasalazine in A549 cells.
Okamoto K; Saito Y; Ueda H; Narumi K; Furugen A; Kobayashi M
Biopharm Drug Dispos; 2021 Sep; 42(8):389-392. PubMed ID: 34287957
[TBL] [Abstract][Full Text] [Related]
6. Cystine/Glutamate Antiporter (xCT) Is Required for Chief Cell Plasticity After Gastric Injury.
Meyer AR; Engevik AC; Willet SG; Williams JA; Zou Y; Massion PP; Mills JC; Choi E; Goldenring JR
Cell Mol Gastroenterol Hepatol; 2019; 8(3):379-405. PubMed ID: 31071489
[TBL] [Abstract][Full Text] [Related]
7. Redox-dependent AMPK inactivation disrupts metabolic adaptation to glucose starvation in xCT-overexpressing cancer cells.
Lee Y; Itahana Y; Ong CC; Itahana K
J Cell Sci; 2022 Aug; 135(15):. PubMed ID: 35775474
[TBL] [Abstract][Full Text] [Related]
8. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility.
Shin CS; Mishra P; Watrous JD; Carelli V; D'Aurelio M; Jain M; Chan DC
Nat Commun; 2017 Apr; 8():15074. PubMed ID: 28429737
[TBL] [Abstract][Full Text] [Related]
9. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer.
Koppula P; Zhang Y; Zhuang L; Gan B
Cancer Commun (Lond); 2018 Apr; 38(1):12. PubMed ID: 29764521
[TBL] [Abstract][Full Text] [Related]
10. High cell density increases glioblastoma cell viability under glucose deprivation via degradation of the cystine/glutamate transporter xCT (SLC7A11).
Yamaguchi I; Yoshimura SH; Katoh H
J Biol Chem; 2020 May; 295(20):6936-6945. PubMed ID: 32265299
[TBL] [Abstract][Full Text] [Related]
11. Cystine-glutamate antiporter xCT as a therapeutic target for cancer.
Liu L; Liu R; Liu Y; Li G; Chen Q; Liu X; Ma S
Cell Biochem Funct; 2021 Mar; 39(2):174-179. PubMed ID: 32749001
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT.
Lien EC; Ghisolfi L; Geck RC; Asara JM; Toker A
Sci Signal; 2017 Dec; 10(510):. PubMed ID: 29259101
[TBL] [Abstract][Full Text] [Related]
13. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
Timmerman LA; Holton T; Yuneva M; Louie RJ; Padró M; Daemen A; Hu M; Chan DA; Ethier SP; van 't Veer LJ; Polyak K; McCormick F; Gray JW
Cancer Cell; 2013 Oct; 24(4):450-65. PubMed ID: 24094812
[TBL] [Abstract][Full Text] [Related]
14. ROS Mediate xCT-Dependent Cell Death in Human Breast Cancer Cells under Glucose Deprivation.
Chen MC; Hsu LL; Wang SF; Hsu CY; Lee HC; Tseng LM
Cells; 2020 Jul; 9(7):. PubMed ID: 32630312
[TBL] [Abstract][Full Text] [Related]
15. Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition.
Muir A; Danai LV; Gui DY; Waingarten CY; Lewis CA; Vander Heiden MG
Elife; 2017 Aug; 6():. PubMed ID: 28826492
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling.
Suina K; Tsuchihashi K; Yamasaki J; Kamenori S; Shintani S; Hirata Y; Okazaki S; Sampetrean O; Baba E; Akashi K; Mitsuishi Y; Takahashi F; Takahashi K; Saya H; Nagano O
Cancer Sci; 2018 Dec; 109(12):3874-3882. PubMed ID: 30298963
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Sehm T; Rauh M; Wiendieck K; Buchfelder M; Eyüpoglu IY; Savaskan NE
Oncotarget; 2016 Nov; 7(46):74630-74647. PubMed ID: 27612422
[TBL] [Abstract][Full Text] [Related]
18. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.
Hassanein M; Hoeksema MD; Shiota M; Qian J; Harris BK; Chen H; Clark JE; Alborn WE; Eisenberg R; Massion PP
Clin Cancer Res; 2013 Feb; 19(3):560-70. PubMed ID: 23213057
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of SLC7A11/xCT creates a vulnerability to selenocystine-induced cytotoxicity.
Tan SLW; Tan HM; Israeli E; Fatihah I; Ramachandran V; Ali SB; Goh SJA; Wee J; Tan AQL; Tam WL; Han W
Biochem J; 2023 Dec; 480(24):2045-2058. PubMed ID: 38078799
[TBL] [Abstract][Full Text] [Related]
20. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
